Legal & General Group PLC Biogen Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Biogen Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 1,548,813 shares of BIIB stock, worth $269 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,548,813

Previous 1,550,839 0.13%

Holding current value

$269 Million

Previous $334 Million 7.37%

% of portfolio

0.08%

Previous 0.08%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $385,993 - $479,594	-2,026 Reduced 0.13%	1,548,813 $359 Million
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $3.58 Million - $4.53 Million	-16,905 Reduced 1.08%	1,550,839 $334 Million
Q4 2023 Feb 15, 2024	BUY	$222.59 - $267.94 $50.9 Million - $61.3 Million	228,666 Added 17.08%	1,567,744 $406 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $7.71 Million - $8.7 Million	-30,443 Reduced 2.22%	1,339,078 $344 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $3.02 Million - $3.49 Million	10,974 Added 0.81%	1,369,521 $390 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $5.67 Million - $6.46 Million	-22,112 Reduced 1.6%	1,358,547 $378 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $12.3 Million - $15 Million	-48,840 Reduced 3.42%	1,380,659 $382 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $5.15 Million - $7.11 Million	-26,471 Reduced 1.82%	1,429,499 $382 Million
Q2 2022 Aug 22, 2022	BUY	$187.54 - $223.02 $2.93 Million - $3.48 Million	15,609 Added 1.08%	1,455,970 $297 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $15.9 Million - $20.1 Million	82,281 Added 6.06%	1,440,361 $303 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $10.8 Million - $13.8 Million	-48,116 Reduced 3.42%	1,358,080 $326 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $5.8 Million - $7.57 Million	20,504 Added 1.48%	1,406,196 $398 Million
Q2 2021 Aug 12, 2021	BUY	$259.0 - $414.71 $49.1 Million - $78.7 Million	189,746 Added 15.87%	1,385,692 $480 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $8.39 Million - $9.83 Million	-34,528 Reduced 2.81%	1,195,946 $335 Million
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $10.6 Million - $15.9 Million	-44,714 Reduced 3.51%	1,230,474 $301 Million
Q3 2020 Nov 13, 2020	SELL	$264.77 - $305.71 $9.33 Million - $10.8 Million	-35,245 Reduced 2.69%	1,275,188 $362 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $12.9 Million - $17.1 Million	49,950 Added 3.96%	1,310,433 $351 Million
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $1.36 Million - $1.73 Million	5,075 Added 0.4%	1,260,483 $399 Million
Q4 2019 Feb 13, 2020	BUY	$220.06 - $304.07 $3.46 Million - $4.78 Million	15,724 Added 1.27%	1,255,408 $373 Million
Q3 2019 Nov 13, 2019	BUY	$217.44 - $243.88 $3.7 Million - $4.15 Million	17,002 Added 1.39%	1,239,684 $289 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $1.73 Million - $1.91 Million	-7,884 Reduced 0.64%	1,222,682 $286 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $48.9 Million - $76.4 Million	225,455 Added 22.43%	1,230,566 $291 Million
Q4 2018 Feb 15, 2019	BUY	$278.5 - $352.75 $15.4 Million - $19.5 Million	55,176 Added 5.81%	1,005,111 $302 Million
Q3 2018 Nov 20, 2018	SELL	$293.51 - $383.83 $6.53 Million - $8.54 Million	-22,260 Reduced 2.29%	949,935 $336 Million
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $12.7 Million - $15.1 Million	-49,251 Reduced 4.82%	972,195 $282 Million
Q1 2018 May 17, 2018	SELL	$260.13 - $367.91 $10.8 Million - $15.3 Million	-41,690 Reduced 3.92%	1,021,446 $280 Million
Q4 2017 Feb 13, 2018	BUY	$307.64 - $344.58 $327 Million - $366 Million	1,063,136	1,063,136 $339 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Biogen Inc. Transaction History